Towards a 21st-century roadmap for biomedical research and drug discovery: consensus report and recommendations.

[1]  A. Muotri,et al.  Modeling autism spectrum disorders with human neurons , 2017, Brain Research.

[2]  S. Bhatia,et al.  Engineering a perfusable 3D human liver platform from iPS cells. , 2016, Lab on a chip.

[3]  A. Muotri.  The Human Model: Changing Focus on Autism Research , 2016, Biological Psychiatry.

[4]  T. Tsukamoto.  Animal disease models for drug screening: the elephant in the room? , 2016, Drug discovery today.

[5]  C. Auffray,et al.  Longitudinally Stable, Clinically Defined Clusters of Patients with Asthma Independently Identified in the ADEPT and U-BIOPRED Asthma Studies. , 2016, Annals of the American Thoracic Society.

[6]  Mitchell R. McGill,et al.  Bile Acid‐Induced Toxicity in HepaRG Cells Recapitulates the Response in Primary Human Hepatocytes , 2016, Basic & clinical pharmacology & toxicology.

[7]  F. Cugola,et al.  Induced pluripotent stem cells for modeling neurological disorders. , 2015, World journal of transplantation.

[8]  Martin Hofmann-Apitius,et al.  Bioinformatics Mining and Modeling Methods for the Identification of Disease Mechanisms in Neurodegenerative Disorders , 2015, International journal of molecular sciences.

[9]  F. Noor.  A shift in paradigm towards human biology‐based systems for cholestatic‐liver diseases , 2015, The Journal of physiology.

[10]  Hiroaki Kitano,et al.  Lessons from Toxicology: Developing a 21st-Century Paradigm for Medical Research , 2015, Environmental health perspectives.

[11]  Martin Hofmann-Apitius,et al.  Computable cause-and-effect models of healthy and Alzheimer's disease states and their mechanistic differential analysis , 2015, Alzheimer's & Dementia.

[12]  Young Hye Kim,et al.  Alzheimer's in 3D culture: Challenges and perspectives , 2015, BioEssays : news and reviews in molecular, cellular and developmental biology.

[13]  A. Guillouzo,et al.  Cellular Accumulation and Toxic Effects of Bile Acids in Cyclosporine A-Treated HepaRG Hepatocytes. , 2015, Toxicological sciences : an official journal of the Society of Toxicology.

[14]  C. David Page,et al.  Human pluripotent stem cell-derived neural constructs for predicting neural toxicity , 2015, Proceedings of the National Academy of Sciences.

[15]  Xi Chen,et al.  Development of a microfluidic platform with integrated power splitting waveguides for optogenetic neural cell stimulation , 2015, Biomedical microdevices.

[16]  Borislav D. Dimitrov,et al.  Innate and adaptive T cells in asthmatic patients: Relationship to severity and disease mechanisms , 2015, The Journal of allergy and clinical immunology.

[17]  J. Lupski,et al.  Altered neuronal network and rescue in a human MECP2 duplication model , 2015, Molecular Psychiatry.

[18]  A. Guillouzo,et al.  Comparative Localization and Functional Activity of the Main Hepatobiliary Transporters in HepaRG Cells and Primary Human Hepatocytes. , 2015, Toxicological sciences : an official journal of the Society of Toxicology.

[19]  H. Griffiths,et al.  Developing accurate models of the human airways , 2015, The Journal of pharmacy and pharmacology.

[20]  James Adjaye,et al.  Induced pluripotent stem cell-derived neuronal cells from a sporadic Alzheimer’s disease donor as a model for investigating AD-associated gene regulatory networks , 2015, BMC Genomics.

[21]  A. V. D. Stolpe,et al.  Innovative human-specific investigational approaches to autoimmune disease , 2015 .

[22]  S. Dahlén,et al.  Human tissue models for a human disease: what are the barriers? , 2015, Thorax.

[23]  Donald E Ingber,et al.  Engineered in vitro disease models. , 2015, Annual review of pathology.

[24]  Amy Y. Chen,et al.  Notch2 is required for inflammatory cytokine-driven goblet cell metaplasia in the lung. , 2015, Cell reports.

[25]  Rudolph E. Tanzi,et al.  Effect of potent γ-secretase modulator in human neurons derived from multiple presenilin 1-induced pluripotent stem cell mutant carriers. , 2014, JAMA neurology.

[26]  Stefan Przyborski,et al.  Advances in 3D cell culture technologies enabling tissue‐like structures to be created in vitro , 2014, Journal of anatomy.

[27]  M. Macleod,et al.  Two decades testing interventions in transgenic mouse models of Alzheimer ’ s disease : designing and interpreting studies for clinical trial success , 2014 .

[28]  C. Corrigan,et al.  Sphingosine-1-phosphate induces pro-remodelling response in airway smooth muscle cells , 2014, Allergy.

[29]  G. Langley.  Considering a new paradigm for Alzheimer's disease research. , 2014, Drug discovery today.

[30]  Kathy E. O’Neill,et al.  An organized and functional thymus generated from FOXN1-reprogrammed fibroblasts , 2014, Nature Cell Biology.

[31]  Thomas Hartung,et al.  Biological and medical applications of a brain-on-a-chip , 2014, Experimental biology and medicine.

[32]  Michael B Bracken,et al.  Is animal research sufficiently evidence based to be a cornerstone of biomedical research? , 2014, BMJ : British Medical Journal.

[33]  M. Cazzola,et al.  Advances in asthma drug discovery: evaluating the potential of nasal cell sampling and beyond , 2014, Expert opinion on drug discovery.

[34]  Uwe Marx,et al.  Human immunity in vitro - solving immunogenicity and more. , 2014, Advanced drug delivery reviews.

[35]  F. Noor,et al.  3D organotypic HepaRG cultures as in vitro model for acute and repeated dose toxicity studies. , 2014, Toxicology in vitro : an international journal published in association with BIBRA.

[36]  Elias A. Zerhouni,et al.  Turning the Titanic , 2014, Science Translational Medicine.

[37]  Martin Hofmann-Apitius,et al.  Biomarker-guided translation of brain imaging into disease pathway models , 2013, Scientific Reports.

[38]  Imran Shah,et al.  Development of an adverse outcome pathway from drug-mediated bile salt export pump inhibition to cholestatic liver injury. , 2013, Toxicological sciences : an official journal of the Society of Toxicology.

[39]  A. van den Berg,et al.  Three-dimensional co-cultures of human endothelial cells and embryonic stem cell-derived pericytes inside a microfluidic device. , 2013, Lab on a chip.

[40]  B. van Wilgenburg,et al.  Efficient, Long Term Production of Monocyte-Derived Macrophages from Human Pluripotent Stem Cells under Partly-Defined and Fully-Defined Conditions , 2013, PloS one.

[41]  D. Altshuler,et al.  Validating therapeutic targets through human genetics , 2013, Nature Reviews Drug Discovery.

[42]  W. Lucchesi,et al.  The utility of patient specific induced pluripotent stem cells for the modelling of Autistic Spectrum Disorders , 2013, Psychopharmacology.

[43]  W. Lucchesi,et al.  The utility of patient specific induced pluripotent stem cells for the modelling of Autistic Spectrum Disorders , 2013, Psychopharmacology.

[44]  Elmar Heinzle,et al.  3D organotypic cultures of human HepaRG cells: a tool for in vitro toxicity studies. , 2013, Toxicological sciences : an official journal of the Society of Toxicology.

[45]  J Emnéus,et al.  Modular microfluidic system as a model of cystic fibrosis airways. , 2012, Biomicrofluidics.

[46]  K. Mullane,et al.  Translational semantics and infrastructure: another search for the emperor's new clothes? , 2012, Drug discovery today.

[47]  J. Scannell,et al.  Diagnosing the decline in pharmaceutical R&D efficiency , 2012, Nature Reviews Drug Discovery.

[48]  Gemma Buckland.  Harnessing opportunities in non-animal asthma research for a 21st-century science. , 2011, Drug discovery today.

[49]  D. Van Dam,et al.  Animal models in the drug discovery pipeline for Alzheimer's disease , 2011, British journal of pharmacology.

[50]  H. Hioki,et al.  Anti-Aβ Drug Screening Platform Using Human iPS Cell-Derived Neurons for the Treatment of Alzheimer's Disease , 2011, PloS one.

[51]  Kimberly Scearce-Levie,et al.  Animal Models of Alzheimer's Disease: Modeling Targets, Not Disease Accelerating Drug Discovery for Alzheimer's Disease: Best Practices for Preclinical Animal Studies , 2022 .

[52]  I. Kola,et al.  A call to reform the taxonomy of human disease , 2011, Nature Reviews Drug Discovery.

[53]  Stephen T Holgate,et al.  Animal models of asthma: value, limitations and opportunities for alternative approaches. , 2011, Drug discovery today.

[54]  Fred H. Gage,et al.  A Model for Neural Development and Treatment of Rett Syndrome Using Human Induced Pluripotent Stem Cells , 2010, Cell.

[55]  Nader Moazami,et al.  Multiscale imaging of the human heart: Building the foundation for human systems physiology and translational medicine , 2010, 2010 Annual International Conference of the IEEE Engineering in Medicine and Biology.

[56]  D. Ingber,et al.  Reconstituting Organ-Level Lung Functions on a Chip , 2010, Science.

[57]  Daniel L Villeneuve,et al.  Adverse outcome pathways: A conceptual framework to support ecotoxicology research and risk assessment , 2010, Environmental toxicology and chemistry.

[58]  Tommy B Andersson,et al.  Evaluation of HepaRG Cells as an in Vitro Model for Human Drug Metabolism Studies , 2008, Drug Metabolism and Disposition.

[59]  F. Pistollato,et al.  A Human-Based Integrated Framework for Alzheimer's Disease Research. , 2015, Journal of Alzheimer's disease : JAD.

[60]  Shibashish Giri,et al.  A low-cost, high-quality new drug discovery process using patient-derived induced pluripotent stem cells. , 2015, Drug discovery today.

[61]  Eric E Schadt,et al.  Systems biology of asthma and allergic diseases: a multiscale approach. , 2015, The Journal of allergy and clinical immunology.

[62]  K. Mullane,et al.  Animal models of asthma: reprise or reboot? , 2014, Biochemical pharmacology.